December 6, 2017 — French company Robocath, which designs and develops robotic solutions for the treatment of vascular diseases, announced an increase in capital of €1.7 million ($2 million). This is partly thanks to a €1.25 million ($1.5 million) contribution from Crédit Agricole Innovations et Territoires (CAIT), a fund dedicated to technological innovation in France, managed by Supernova Invest. Cardio Participation, a holding company bringing together several business angels, also invested €450,000 ($530,000). This latest financial contribution supplements the €4.7 million ($5.6 million) raised by Robocath in a previous round of fundraising in May.
Robocath’s R-One technology optimizes and increases the safety of robotic-assisted coronary angioplasty. The technology allows the surgeon to operate with extreme precision and in optimal conditions. Intuitive to use, R-One allows the surgeon to operate from a seated position and to use a portable protective screen to guard against X-rays. This first robotic platform will be marketed in Europe and the Middle East in 2018.
Thanks to this funding, Robocath will also begin researching and developing the next generation of robotic solutions. The new platform will be used to treat neurovascular diseases such as strokes, the second leading cause of death in the world after hearts attacks. The new solution will also aim to improve care for these conditions.
For more information: www.robocath.com
May 13, 2026 
